We were delighted to have the honour of speaking to Jeffrey Cohen (Cleveland Clinic, Cleveland, OH, USA), the president of the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS). He shared positive findings and expert insight from the phase 3 INROADS study, which investigated the safety and efficacy of amantadine extended release capsules in patients with multiple sclerosis with walking impairment (ClinicalTrials.gov identifier: NCT03436199). This discussion was based on his MSVirtual2020 presentation: P0225 – Phase 3 Study Results Assessing the Efficacy and Safety of ADS-5102 (Amantadine) Extended Release Capsules in MS Patients with Walking Impairment.
Questions
1. What are the limitations of current therapies for walking impairment in people with multiple sclerosis (MS)? (0:06)
2. What is the rationale for the use of amantadine in patients with MS and walking impairment? (0:51)
3. Could you tell us a little about the pharmacokinetics of ADS-5102 and its advantages over immediate release formulations of amantadine in MS therapy? (1:24)
4. Could you give us an overview of the INROADS study and its major findings? (2:12)
5. What are the clinical implications of these findings and what future studies are planned? (3:18)
Disclosures: Dr Cohen reports receiving personal compensation for consulting for Adamas, Atara, Bristol-Myers Squibb, Convelo, MedDay, and Mylan; and serving as an Editor of Multiple Sclerosis Journal.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of the Joint ACTRIMS-ECTRIMS Meeting, MSVirtual2020.
